<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03035591</url>
  </required_header>
  <id_info>
    <org_study_id>3121001</org_study_id>
    <nct_id>NCT03035591</nct_id>
  </id_info>
  <brief_title>ODM-207 in Patients With Advance Solid Tumours</brief_title>
  <acronym>BETIDES</acronym>
  <official_title>Safety and Pharmacokinetics of ODM-207 in Patients With Selected Advanced Solid Tumours: an Open-label, Non-randomised, Uncontrolled, Multicentre, First-in-human Study With Cohort Expansion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-man study to assess the safety and tolerability and to characterise the
      pharmacokinetics of ODM-207.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>28 days</time_frame>
    <description>Highest dose level at which &lt;33% of patients in a cohort experience Dose Limiting Toxicity (DLT)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ODM-207</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of ODM-207</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-207</intervention_name>
    <arm_group_label>ODM-207</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically or cytologically confirmed locally advanced or metastatic
             cancer for which no effective standard therapy exists or are refractory or resistant
             to conventional therapy

          -  Life expectancy &gt;12 weeks

          -  Patient may have either measurable or non-measurable disease, but must have disease
             that can be evaluated for improvement of progression

          -  ECOG performance status of 0 to 1

        Exclusion Criteria:

          -  History of bleeding disorder or significant bleeding episode within 6 months prior to
             study treatment

          -  Subjects receiving anticoagulants or medications that durably inhibit platelet
             function (7-day wash-out prior to study treatment)

          -  History of or current leptomeningeal or brain metastasis or spinal cord compression.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johann De Bono</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICR/Royal Marsden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew J Wighton</last_name>
    <phone>+44 115 9487124</phone>
    <email>andrew.wighton@orionpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Central Hospital, Department of Oncology</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petri Bono, MD</last_name>
      <phone>+358 9 471 75380</phone>
      <email>petri.bono@hus.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2017</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

